Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ibuprofen studies
Meta analysis
Home COVID-19 treatment researchIbuprofenIbuprofen (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -23% Improvement Relative Risk Mortality (b) 17% Ibuprofen for COVID-19  Wong et al.  Prophylaxis Is prophylaxis with ibuprofen beneficial for COVID-19? Retrospective 1,977,972 patients in the United Kingdom (Mar - Jun 2020) Higher mortality with ibuprofen (not stat. sig., p=0.19) Wong et al., Annals of the Rheumatic D.., Jan 2021 Favors ibuprofen Favors control

Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts

Wong et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-219517
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 2,463,707 people in the UK, showing no significant difference in COVID-19 mortality with NSAID use. Current NSAID users were defined as those ever prescribed an NSAID in the 4 months prior to study start, and non-users were those with no record of NSAID prescription in the same time period.
risk of death, 23.0% higher, HR 1.23, p = 0.19, adjusted per study, general population, multivariable.
risk of death, 17.0% lower, HR 0.83, p = 0.37, adjusted per study, rheumatoid arthritis/osteoarthritis patients, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wong et al., 21 Jan 2021, retrospective, United Kingdom, peer-reviewed, median age 53.0, 32 authors, study period 1 March, 2020 - 14 June, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIbuprofenAll
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
Dr Angel Ys Wong, Brian Mackenna, Caroline E Morton, Anna Schultze, Alex J Walker, Krishnan Bhaskaran, Jeremy P Brown, Christopher T Rentsch, Elizabeth Williamson, Henry Drysdale, Richard Croker, Seb Bacon, William Hulme, Chris Bates, Helen J Curtis, Amir Mehrkar, David Evans, Peter Inglesby, Jonathan Cockburn, Helen I Mcdonald, Laurie Tomlinson, Rohini Mathur, Kevin Wing, Harriet Forbes, Rosalind M Eggo, John Parry, Frank Hester, Sam Harper, Stephen Jw Evans, Liam Smeeth, Ian J Douglas, Ben Goldacre
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-219517
Objectives To assess the association between routinely prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and deaths from COVID-19 using OpenSAFELY, a secure analytical platform. Methods We conducted two cohort studies from 1 March to 14 June 2020. Working on behalf of National Health Service England, we used routine clinical data in England linked to death data. In study 1, we identified people with an NSAID prescription in the last 3 years from the general population. In study 2, we identified people with rheumatoid arthritis/osteoarthritis. We defined exposure as current NSAID prescription within the 4 months before 1 March 2020. We used Cox regression to estimate HRs for COVID-19 related death in people currently prescribed NSAIDs, compared with those not currently prescribed NSAIDs, accounting for age, sex, comorbidities, other medications and geographical region. Results In study 1, we included 536 423 current NSAID users and 1 927 284 non-users in the general population. We observed no evidence of difference in risk of COVID-19 related death associated with current use (HR 0.96, 95% CI 0.80 to 1.14) in the multivariable-adjusted model. In study 2, we included 1 708 781 people with rheumatoid arthritis/osteoarthritis, of whom 175 495 (10%) were current NSAID users. In the multivariable-adjusted model, we observed a lower risk of COVID-19 related death (HR 0.78, 95% CI 0.64 to 0.94) associated with current use of NSAID versus non-use. Conclusions We found no evidence of a harmful effect of routinely prescribed NSAIDs on COVID-19 related deaths. Risks of COVID-19 do not need to influence decisions about the routine therapeutic use of NSAIDs. INTRODUCTION COVID-19, caused by the SARS-CoV-2, has been diagnosed in approximately 18 million patients with >690 000 deaths in >200 countries as of 5 August 2020. 1 Key messages What is already known about this subject? ► There have been concerns that non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of COVID-19 disease. Recent observational studies reported no evidence of a harmful effect of NSAID use on COVID-19 severity among patients with COVID-19. ► However, most studies were of much smaller sample size, not general population based or did not specifically investigate individual NSAIDs (eg, naproxen and ibuprofen). ► In addition, limited clinical data are available to advise patients using long-term NSAID treatment (including people with rheumatoid arthritis and osteoarthritis) whether the treatment should be continued or stopped in the context of COVID-19 pandemic. What does this study add? ► We identified two study populations (2 463 707 people who ever used NSAIDs in the past 3 years from the general population and 1 708 781 people with rheumatoid arthritis/ osteoarthritis) in England using OpenSAFELY platform. We then grouped them into current users and non-users, respectively, in each study population. ► In both populations, no association between..
Abbreviations: COPD, Chronic obstructive pulmonary disease; DMARDs, Disease-modifying antirheumatic drugs. BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s)
Amici, Caro, Ciucci, Indomethacin has a potent antiviral activity against SARS coronavirus, Antivir Ther
Bancos, Bernard, Topham, Ibuprofen and other widely used nonsteroidal anti-inflammatory drugs inhibit antibody production in human cells, Cell Immunol, doi:10.1016/j.cellimm.2009.03.007
Basille, Thomsen, Madsen, Nonsteroidal antiinflammatory drug use and clinical outcomes of community-acquired pneumonia, Am J Respir Crit Care Med, doi:10.1164/rccm.201802-0229LE
Bourgeois, Ferroni, Leruez-Ville, Nonsteroidal anti-inflammatory drug without antibiotics for acute viral infection increases the empyema risk in children: a matched case-control study, J Pediatr, doi:10.1016/j.jpeds.2016.05.025
Bruce, Barlow-Pay, Short, Prior routine use of non-steroidal antiinflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19, J Clin Med, doi:10.3390/jcm9082586
Byington, Spencer, Johnson, An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations, Clin Infect Dis, doi:10.1086/338460
Choi, Ahn, Ryu, Clinical characteristics and disease progression in early-stage COVID-19 patients in South Korea, J Clin Med, doi:10.3390/jcm9061959
Clinicaltrials, Gov, Efficacy of addition of naproxen in the treatment of critically ill patients hospitalized for COVID-19 infection
Clinicaltrials, Gov, Evaluate the efficacy and safety of oral hydroxychloroquine, indomethacin and Zithromax in subjects with mild symptoms of COVID-19
Clinicaltrials, Gov, Inhaled ibuprofen to treat COVID-19
Clinicaltrials, Liberate trial in COVID-19
Ding, Vanderweele, Sensitivity analysis without assumptions, Epidemiology, doi:10.1097/EDE.0000000000000457
Fang, Karakiulakis, Roth, Gu, Xie et al., Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med, doi:10.1038/srep19840
Francisco, EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 -European Medicines Agency
François, Desrumaux, Cans, Prevalence and risk factors of suppurative complications in children with pneumonia, Acta Paediatr, doi:10.1111/j.1651-2227.2010.01734.x
Gianfrancesco, Hyrich, Al-Adely, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217871
Goldacre, Mackenna, The NHS deserves better use of hospital medicines data, BMJ, doi:10.1136/bmj.m2607
Imam, Odish, Gill, Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States, J Intern Med, doi:10.1111/joim.13119
Kaplan, Edelson, Korchak, Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo, Biochem Pharmacol, doi:10.1016/0006-2952(84)90228-4
Kotsiou, Zarogiannis, Gourgoulianis, Prehospital NSAIDs use prolong hospitalization in patients with pleuro-pulmonary infection, Respir Med, doi:10.1016/j.rmed.2016.12.005
Little, Moore, Kelly, Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial, BMJ, doi:10.1136/bmj.f6041
Lund, Kristensen, Reilev, Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study, PLoS Med, doi:10.1371/journal.pmed.1003308
Mancia, Rea, Ludergnani, Renin-Angiotensin-Aldosterone system blockers and the risk of Covid-19, N Engl J Med, doi:10.1056/NEJMoa2006923
Matthews, Donaldson, Evans, Safety of medicines delivered by homecare companies, BMJ, doi:10.1136/bmj.k2201
Messika, Sztrymf, Bertrand, Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients, J Crit Care, doi:10.1016/j.jcrc.2014.05.021
Nhs England, Guidance on conditions for which over the counter items should not routinely be prescribed in primary care
Nhsengland, Local sustainability and transformation partnership
Qiao, Wang, Chen, Ibuprofen attenuates cardiac fibrosis in streptozotocininduced diabetic rats, Cardiology, doi:10.1159/000375362
Rheum Dis, 58mmols/mol) Uncontrolled (HbA1c ≥ 58mmols, /mol)
Rheum Dis, 58mmols/mol) Uncontrolled (HbA1c ≥ 58mmols, /mol)
Rheum Dis, 58mmols/mol) Uncontrolled (HbA1c ≥ 58mmols/mol)
Rheum Dis, 58mmols/mol) Uncontrolled (HbA1c ≥ 58mmols/mol)
Rheum Dis, Controlled (HbA1c < 58mmols, /mol)
Rinott, Kozer, Shapira, Ibuprofen use and clinical outcomes in COVID-19 patients, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.06.003
Vaja, Chan, Ferreira, The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections, Br J Clin Pharmacol, doi:10.1111/bcp.14514
Voiriot, Dury, Parrot, Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia, Chest, doi:10.1378/chest.09-3102
Voiriot, Philippot, Elabbadi, Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients, J Clin Med, doi:10.3390/jcm8060786
Who, Emergency use ICD codes for COVID-19 disease outbreak
Williamson, Walker, Bhaskaran, Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4
Yousefifard, Zali, Zarghi, Non-Steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence, Int J Clin Pract, doi:10.1111/ijcp.13557
Zou, Yan, Shu, Angiotensin-Converting enzyme 2 protects from lethal avian influenza A H5N1 infections, Nat Commun, doi:10.1038/ncomms4594
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop